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Members of the chromodomain-helicase-DNA binding (CHD) protein family are chromatin
remodelers implicated in human pathologies, with CHD6 being one of its least studied
members. We discovered a de novo CHD6 missense mutation in a patient clinically pre-
senting the rare Hallermann-Streiff syndrome (HSS). We used genome editing to generate
isogenic iPSC lines and model HSS in relevant cell types. By combining genomics with
functional in vivo and in vitro assays, we show that CHD6 binds a cohort of autophagy and
stress response genes across cell types. The HSS mutation affects CHD6 protein folding and
impairs its ability to recruit co-remodelers in response to DNA damage or autophagy sti-
mulation. This leads to accumulation of DNA damage burden and senescence-like pheno-
types. We therefore uncovered a molecular mechanism explaining HSS onset via chromatin
control of autophagic flux and genotoxic stress surveillance.
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Modulation of DNA accessibility is central to the reg-ulation of eukaryotic genome functions like transcrip-tion, DNA replication, or repair1–3. One large class of
enzymes, the ATP-dependent chromatin remodeling factors, can
alter DNA accessibility by removing or repositioning nucleosomal
proteins along chromosomes. In mammals, the chromodomain-
helicase-DNA binding (CHD) proteins represent the largest
family of remodelers. In humans, all nine of its members are
characterized by the presence of tandem N-terminal chromodo-
mains and by a central SNF2-like ATPase module. Additional
domains allow for the further classification of these large (>200
kDa) proteins into three subfamilies. Subfamily I includes CHD1
and -2 that carry DNA binding domains absent from subfamily II
members CHD3-5; these instead have tandem plant home-
odomains that bind histone tails. Subfamily III includes CHD6-9,
marked by the presence of Brahma/Kismet (BRK) and SANT-like
domains closer to their C-termini4,5. SANT domains, initially
discovered in co-repressor proteins, were later found in different
remodeling complex subunits as modules that may couple
histone-tail binding to enzymatic activity6. The CHD SANT/
SLIDE domains, which resemble Myb DNA‐binding domains, are
conserved between CHD and ISWI proteins. Data suggest that
the SANT and SLIDE modules interact with DNA as one coop-
erative unit important for tuning DNA binding and nucleosome
spacing7.
Mutations in subfamily III members have been causally
implicated in autism (CHD7 and -8)8–10 and CHARGE syn-
drome (CHD7)11–13. CHD6 is a far less studied member of this
subfamily. To date, CHD6 has not been functionally linked to a
human pathology, but there exist reports of large translocations
encompassing its locus in one Pitt-Hopkins patient14, in a single
case of mental retardation15, and in sporadic acute myeloid leu-
kemia incidences16. In the only existing CHD6 mouse model,
where exon 12 (encoding its conserved ATPase domain) is
lacking, no obvious phenotype apart from mild ataxia was
observed17. At the molecular level, CHD6 is ubiquitously-
expressed and resides alongside RNA polymerases at nucleo-
plasmic sites of nascent RNA synthesis as part of supramolecular
complexes18. Recent reports implicated CHD6 in the repression
of viral replication19, in the topological organization of the CFTR
locus20, and in chromatin remodeling at sites of oxidative DNA
damage21.
Human cells continuously face genotoxic stress throughout
development, and mechanisms are in place to survey and restore
any resulting DNA damage. Weakening of these mechanisms
leads to DNA damage accumulation and is now understood to
cause premature ageing syndromes (known as segmental
progerias)22. For example, the well-studied Hutchinson-Gilford
and Werner progerias stem from mutations in LMNA and
RECQL2, respectively, which promote genome instability23,24.
Alongside increased DNA damage burden, deregulated autop-
hagy constitutes another ageing hallmark. Autophagy is a
housekeeping catabolic pathway essential for recycling long-lived
organelles and misfolded proteins, and is activated by various
stimuli, including growth factor withdrawal, nutrient deprivation,
infection, oxidative stress, or hypoxia25. A link between autop-
hagy induction and the DNA damage response was recently
documented26,27. Interestingly, mouse models with conditional,
tissue-specific knockout of key autophagy regulators present age-
associated defects28.
Hallermann-Streiff syndrome (HSS; OMIM ID: #234100) is a
rare congenital disorder characterized by craniofacial and dental
dysmorphisms with a specific facial gestalt, eye malformations,
distinctive facial features, hair and skin abnormalities, and short
stature. Due to its clinical course and progression, HSS is regar-
ded as a premature ageing disorder29–31. With just few cases
reported to date, and with virtually all reports being descriptive,
there is an apparent need for dissecting the molecular pathways
underlying HSS32. Here, we report a de novo missense mutation
in CHD6 from an HSS patient that motivated us to dissect the
function of this remodeler. We modeled HSS by generating iso-
genic induced pluripotent stem cell (iPSC) lines carrying the
CHD6 mutation. Using these lines in genomics, biochemical and
functional studies, we provide molecular insights into HSS
etiology. We identify CHD6 as a major housekeeping regulator of
stress and autophagy response genes. Its HSS mutation interferes
with co-factor recruitment to CHD6 target loci, resulting in
compromised autophagy flux, DNA damage accumulation, and
the development of senescence-like phenotypes.
Results
Identification of a putatively-causative HSS mutation and
generation of an iPSC model. To understand the molecular basis
of HSS, we sought to identify genetic mutations associated with
the disease. Despite the rarity of HSS samples, whole-exome
sequencing of blood and saliva-derived DNA from a patient and
parents uncovered a single de novo missense mutation resulting
in an isoleucine to methionine (I1600M) amino acid exchange in
the CHD6 coding sequence. This putatively-causative hetero-
zygous mutation in CHD6 maps to its predicted second SLIDE
domain, at a position which is highly conserved across species
and also present in the SLIDE domain of CHD1 (Fig. 1a and
Supplementary Fig. 1a). We generated iPSCs from this patient by
reprograming fibroblasts from a skin biopsy. Reprograming was
confirmed by assessing pluripotency markers at the RNA and
protein levels (Fig. 1b and Supplementary Fig. 1b) and by testing
the ability of patient-derived iPSCs to form embryonic bodies
(Supplementary Fig. 1c) and differentiate in an undirected
manner into all three germ layers (Supplementary Fig. 1d–f). As
controls for these tests, we used previously characterized age- and
sex-matched wild-type iPSCs33. However, these lines do not have
identical genomic backgrounds, which may complicate data
interpretation. To address this, we applied different CRISPR-Cas9
editing approaches to our control iPSCs to generate isogenic lines
carrying the CHD6 mutation. We obtained two independent lines
expressing only mutated CHD6, and another two lines hetero-
zygously expressing wild-type and mutant CHD6, like in the HSS
patient (Fig. 1c and Supplementary Fig. 1g). These lines were
diploid and karyotypically stable (Supplementary Data File 1),
and could be efficiently differentiated into neural crest cells
(NCCs) or spontaneously-contracting cardiomyocytes (CMs)
(Fig. 1d, e and Supplementary Fig. 1h, i). NCCs were initially
chosen because HSS invariably presents as a neurocristopathy32,
and CMs were chosen since progressing cardiomyopathy has
been reported in some patients34,35. Collectively, we established a
model to study the mechanism underlying HSS in disease-
relevant cell types, while also characterizing CHD6 function in
both a proliferative and a post-mitotic cellular context.
The I1600M CHD6 mutation affects gene expression and
development. We first assessed how this CHD6 mutation affects
gene expression by generating transcriptome profiles from all
genotypes. Given the importance of NCCs in neurocristopathy-
type syndromes, we performed gene set enrichment analysis
against the KEGG pathway database using total cell RNA-seq
data from two independent clones of patient-derived and gene-
edited mutant NCCs. Compared to control cells, we found that
focal adhesion, ECM interactions, p53, MAPK, and pluripotency
signaling were all affected (Fig. 1f). Interestingly, genes known to
be involved in arrhythmogenic cardiomyopathy were also found
to be deregulated (Fig. 1f), and we thus turned to CM RNA-seq
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data analysis. We discovered that many pathways affected in
NCCs are also affected in both patient-derived and gene-edited
mutant CMs (ECM interactions, p53/MAPK/Rap1 signaling,
focal adhesion), while various cardiomyopathy-associated genes
were highlighted (Fig. 1g) despite comparable CHD6 levels
between the different genotypes (Fig. 1h). Finally, we specifically
looked for genes that were commonly deregulated between
patient-derived CMs and NCCs, and found >550 genes associated
with axon guidance, lipid biosynthesis, and heart contraction to
be consistently downregulated compared to wild-type levels
(Supplementary Fig. 1j). On the other hand, >450 genes linked to
cell adhesion, wound healing, apoptosis, and the MAPK and
integrin pathways were consistently upregulated (Supplementary
Fig. 1k).
Given that the deregulation of focal adhesion and integrin
components are central to cell migration, we hypothesized that,
for NCCs especially, the CHD6 mutation could lead to altered
migratory potential. However, in vitro migration assays showed
no significant differences between wild-type and mutant NCCs
(Supplementary Fig. 1l). To also assess this in vivo, we turned to
chicken embryos, a well-established model for NCC studies36,37.
We performed in ovo electroporation to unilaterally overexpress
the human wild-type or I1600M mutant CHD6 directly into the
neural tube and anterior brain of developing chicken embryos at
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Hamburger-Hamilton (HH) developmental stage 9 (HH9).
Following reincubation, embryo phenotypes were assessed at
stage HH20, when wtCHD6-expressing cells displayed the
expected migration to the cornea, heart, and along the neural
tube (Fig. 1i, top left). In contrast, mutCHD6-expressing cells
accumulated more in the neural tube and brain of the embryo
(Fig. 1i, bottom left). Critically, 2/3 of embryos displayed severe
facial malformations, lack of the 1st, or fusion of the 1st and 2nd
branchial arches, enlarged forebrain, as well as diminished
mesenchymal tissue, all of which are reminiscent of HSS
phenotypes (Fig. 1i). Moreover, we observed strong effects on
heart development in mutCHD6-overexpressing embryos.
Hematoxylin-eosin (H-E) staining of dissected heart sections
showed delayed development of both ventricles, as well as
morphological aberrations of the septum (Fig. 1j). These data are
in line with our transcriptome analyses and demonstrate how a
single CHD6 mutation can severely impact development and
gene expression.
CHD6 binds autophagy-relevant genes across cell types. To
infer which of the deregulated genes above were direct CHD6
targets, we applied a tailored crosslinking and ChIP protocol to
iPSCs, NCCs, and CMs of all genotypes (see “Methods”, Fig. 2a
and Supplementary Fig. 2a, b). The analysis of our ChIP-seq data
collection revealed two unexpected features. First, that mutCHD6,
irrespective of the studied cell type, displayed consistently
stronger peaks and a larger binding repertoire than wtCHD6
(Fig. 2a–c and Supplementary Fig. 2a–d). Although we cannot
formally rule out the possibility that the antibody we used
recognizes CHD6 more strongly when it carries the I1600M
mutation, our observations possibly signify that mutCHD6
resides longer on chromatin. This was, at least in part, corrobo-
rated by ChIP-qPCR enrichment at select gene promoters (Sup-
plementary Fig. 2e) and by cell fractionation western blots in
iPSCs (Supplementary Fig. 2f). Second, CHD6 binds many of the
same loci across the three cell types, predominantly at gene
promoters (Fig. 2c, d and Supplementary Fig. 2a). CHD6-bound
loci in NCCs, CMs, and iPSCs were enriched for genes associated
with autophagy, lysosome formation, catabolism, cell cycle con-
trol, and DNA damage response (Fig. 2e and Supplementary
Fig. 2g, h) suggesting that CHD6 may be involved in regulating
these processes.
In further support of this, we analyzed accessible transcription
factor motifs under CHD6 peaks by combining our ChIP-seq
data with publicly-available DNase I footprints from human
embryonic stem cells (ENCODE ENCSR143TBZ [https://www.
encodeproject.org/annotations/ENCSR143TBZ/]). We found
enrichment for TFEB and TFE3 recognition sequences (Fig. 2f).
In addition, survey of ENCODE ChIP-seq data returned TFEB as
the sole significantly enriched TF signal at CHD6-bound sites
(Supplementary Fig. 2i). Given that TFEB is a major autophagy
and lysosomal-gene regulator38, we performed TFEB ChIP-seq in
iPSCs and confirmed it overlaps ~45% of CHD6 peaks (Fig. 2g
and Supplementary Fig. 2a). Genes bound by both TFEB and
CHD6 were strongly associated with GO terms relevant to
autophagy like “lysosome”, “vacuolar membrane” or “cytoplasmic
endosome” (Fig. 2h).
Contrary to what was seen in mouse ESCs using endogenously
tagged-proteins39, CHD6 binding peaks overlapped some CHD2-
bound positions, but not those occupied by CHD1 or CHD7,
indicating that CHD6 controls disparate pathways (Supplemen-
tary Fig. 2j). Thus, we assessed whether CHD6 regulates gene
expression in response to autophagy cues and whether the
I1600M mutation affects this regulation. To this end, we
subjected wt, het-, and mut-iPSCs to 2h of starvation and
performed 3′-end RNA-seq. Wild-type iPSCs responded via
downregulation of mitochondrial and ribosomal processes, while
mutant cells did not. Mut/het-iPSCs also activated ribosome
biogenesis and proinflammatory genes, and suppressed those
involved in the DNA damage response. Moreover, ERK1/
2 signaling, known to regulate subcellular TFEB localization40,
was also affected (Supplementary Fig. 2k). Looking specifically
at CHD6-bound genes, >200 showed levels deviating from
wild-type upon starvation (Fig. 2i and Supplementary Fig. 2l).
Of these, the genes that showed significant misexpression of the
same trend in both het- and mut-iPSCs were linked to processes
like RNA hydrolysis and modification, cell cycle transition,
vacuole organization, and protein turnover (Fig. 2j). These
data again support a ubiquitous role for CHD6 in regulating
autophagy genes.
The CHD6 mutation deregulates autophagy and increases
DNA damage burden. To assess the involvement of CHD6 in
autophagy regulation, we examined some of its key regulators.
First, patient-derived/mutant NCCs displayed elevated phos-
phorylated ribosomal S6 protein levels (Supplementary Fig. 3a)
possibly signifying intensified glycolysis via partial mTORC1
activation. On the other hand, CHD6-mutant CMs displayed
decreased phospho-S6 levels, suggesting dampened mTORC1
activity (Supplementary Fig. 3b). However, both hinted towards
nuclear depletion of microtubule-associated LC3 protein in
mutant compared to wt cells (Supplementary Fig. 3a, b), which
implies a tendency to activate autophagy despite the absence of
pro-autophagy cues. Both patient-derived and het-CMs show
elevated SIRT1 levels compared to wild-type cells (Supplementary
Fig. 3c), which could explain LC3 relocalization (from the nucleus
to the cytoplasm) due to deacetylation by SIRT1. Again, this
occurs in CHD6-mutant cells in the absence of pro-autophagy
cues. Together, these results indicate autophagy deregulation
in CHD6-mutant NCCs and CMs, while highlighting the
Fig. 1 Generation of isogenic iPSCs and developmental impact of the I1600M CHD6 mutation. a Schematic representation of the CHD6 protein
highlighting key functional protein domains (top) and the HSS-specific I1600M missense mutation in the second SANT/SLIDE domain (bottom).
b Reprogramming skin fibroblasts from an HSS patient carrying the I1600M CHD6 mutation into iPSCs exemplified by immunofluorescence (left) and
pluripotency marker expression levels (mean log2 fold-change; right) in two independent clones. Bar, 5 μM. c Generation of iPSCs monoallelically (left) or
heterozygously expressing I1600M CHD6 (right) using two CRISPR/Cas9 editing strategies. d Derivation of wild-type, monoallelic mutant or patient-
derived cardiomyocytes (CMs; top) and neural crest cells (NCCs; bottom) from iPSCs and detection of lineage-specific marker genes by
immunofluorescence (right). Bar, 5 μM. e RT-qPCR mean mRNA level changes of CM markers (n= 2 independent replicates, except het) from all
genotypes in (d). f Top KEGG pathways misregulated in both patient and mutant NCCs RNA-seq data. g As in (f), but using RNA-seq data from patient and
mutant CMs. h Representative immunofluorescence images of CHD6 distribution in wild-type, patient-derived, and monoallelic mutant CMs. Nuclei were
counterstained by DAPI. Bar, 5 μM. i Overexpression of wild-type (top row) and mutant CHD6 (bottom row) in chicken embryos and examination of lateral
and ventral views at stage HH20 to assess proper development of branchial arches (blue), eyes (red), and jaw (white). The number of embryos analyzed
(n) is also given. j As in (i), but for ventral views of the heart (left) and corresponding H-E tissue stainings (right). C conus, RV right ventricle, LV left
ventricle, A atrium. Bar, 500 μM.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23327-1
4 NATURE COMMUNICATIONS |         (2021) 12:3014 | https://doi.org/10.1038/s41467-021-23327-1 | www.nature.com/naturecommunications
Fig. 2 CHD6 binds autophagy-related genes across different cell types. a Genome browser views of CHD6 ChIP-seq data from wild-type (wt),
monoallelic mutant (mut), heterozygous mutant (het) or patient-derived (pat) NCCs (light blue), CMs (magenta), iPSCs (dark blue) around the GAA
promoter. hESC ENCODE ChIP-seq data for CHD1/7 and histone marks are aligned below. b Line plot (top) and heatmaps (bottom) showing ChIP-seq
signal distribution in the 6 kbp around CHD6-bound sites from wild-type (gray), patient-derived (dark blue), or monoallelic mutant NCCs (light blue). Input
data provide a baseline (dashed). c Venn diagrams showing overlap of CHD6 ChIP-seq peaks from the three indicated NCC genotypes (top) or across cell
types (bottom). *: significantly more than expected by chance; P < 10−4, two-sided hypergeometric test. d Bar plot showing the percent of mutCHD6 ChIP-
seq peaks located at increasing distances upstream or downstream of gene TSSs from all three cell types. e Significantly enriched GO terms associated
with mutCHD6-bound genes in NCCs. f Heatmaps showing TF motif enrichment (over background; blue shades) and associated P-values (red shades)
within accessible DNase I footprints overlapping NCC mutCHD6 ChIP-seq peaks. g Line plot showing TFEB and mutCHD6 ChIP-seq signal overlap at iPSC
peaks. h Significantly enriched GO terms associated with the genes at TFEB/CHD6-shared peaks from (g). i Heatmap showing changes in mRNA levels
(log2) of mutCHD6-bound and differentially-regulated genes upon 2-h starvation of iPSCs. Those up- or downregulated (magenta/blue rectangles) in both
monoallelic- (mut) and heterozygous-mutant iPSCs (het) are highlighted. j Significantly enriched GO terms associated with the genes highlighted in (i).
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differences between the proliferating (NCCs) and post-mitotic
context (CMs).
To further characterize this deregulation, we assessed autop-
hagy flux in iPSCs (used for convenience due to the hypothesized
housekeeping nature of autophagy regulation by CHD6). iPSCs
with mutant CHD6 alleles show accumulation of ATG12/ATG5
dimers that are needed for autophagy activation via LC3I
conversion to LC3II38 (Supplementary Fig. 3d). Upon autophagy
inhibition via chloroquine or bafilomycin A1, we observed
somewhat higher levels of LC3I isoform in mutant compared to
wild-type iPSCs, while upon autophagy induction via short-term
(2 h) starvation or rapamycin, LC3II levels in mutant cells
remained significantly lower than those in wt iPSCs (Fig. 3a and
Supplementary Fig. 3e). In parallel, the levels of the ubiquitin-like
conjugating enzyme ATG3 increased upon starvation or
rapamycin treatment in wt, but not in mutant iPSCs (Fig. 3a).
We then used a GFP-LC3-RFP dual reporter vector41 to monitor
autophagy induction in living cells (see gating strategy in
Supplementary Fig. 4). We found that starvation efficiently
induced autophagy and subsequent lysosome fusion in wild-type
iPSCs (reflected in the increase in the RFP-positive iPSC
fraction), but not in mutant cells (Fig. 3b), which already display
significantly fewer lysosomes per cell (Supplementary Fig. 3f). As
was observed using resting NCCs and CMs, mutant iPSCs show a
tendency to activate autophagy in the absence of pro-autophagy
cues. Finally, the levels and number of puncta of p62, another key
autophagy regulator, change significantly in response to rapamy-
cin or bafilomycin in wild-type iPSCs, but not in mutant cells
where this is dampened (Fig. 3c and Supplementary Fig. 3g).
Colocalization between p62 and LC3 is also affected in mutant
iPSCs (Fig. 3c), indicative of a reduced capacity to activate
autophagy in response to rapamycin. Notably, p62 does not show
elevated steady-state levels in CHD6-mutant cells (Supplementary
Fig. 3g, h). Together, these data implicate CHD6 in the control of
autophagy.
Previous studies have shown that autophagy is necessary for
efficiently implementing DNA damage responses26,27, and we
observed that the intrinsic levels and foci of phospho-γH2A.X
were significantly reduced across mutant cells (Supplementary
Fig. 3d, i, j). Thus, we hypothesized that CHD6-mutant cells may
suffer from a compromised DNA damage response due to
impaired autophagy flux. To test this, we induced DNA double-
strand breaks using etoposide and found that γH2A.X foci were
weaker and more diffuse in mutant compared to wild-type CMs
(Fig. 3d). Interestingly, CHD6 did not redistribute in wild-type
cell nuclei in response to etoposide, nor did it colocalize with
γH2A.X foci (Fig. 3e). Using iPSC and CM extracts in western
blots, we found markedly reduced activation (reflected in
phosphorylation) of several DNA damage response components,
like p53, CHK1/2, and γH2A.X in mutant cells, as well as
inefficient PARP1 cleavage (Supplementary Fig. 3d, k). Moreover,
comet assays showed accumulation of unrepaired DNA in iPSCs
carrying mutant CHD6 alleles (Fig. 3f). Such accumulation could
be recapitulated in wild-type cells when etoposide treatment was
combined with pharmacological inhibition of late-stage autop-
hagy (autolysosome formation and degradation) using
chloroquine42 or spautin43 (Fig. 3g). Impaired DNA damage
response also coincided with mutant iPSCs being less susceptible
to apoptosis and insensitive to G2/M-phase arrest (Fig. 3h, i),
most likely due to impaired signaling (Supplementary Fig. 3d).
Notably, this prosurvival effect could be recapitulated in wild-type
cells via autophagy inhibition using chloroquine or spautin
(Fig. 3h).
Gene expression following DNA damage induction was also
affected, as revealed by 3′-end RNA-seq in our iPSC lines. CHD6-
bound genes commonly deregulated in both mutant and
heterozygous cells were especially enriched for genes associated
with macroautophagy, vacuole organization, cell catabolism,
RNAP elongation, DNA repair, and cell death (Fig. 3j, k). These
expression changes manifested alongside hallmarks of a
senescence-like phenotype in mutant iPSCs, most probably due
to DNA damage accumulation44,45. We recorded reduced levels
of H3K27me3-marked heterochromatin (Supplementary Fig. 3l),
emergence of HP1α foci in constitutive heterochromatin
(Supplementary Fig. 3m), as well as increased β-galactosidase
staining (Supplementary Fig. 3n). Importantly, these last two
features could be recapitulated following autophagy inhibition by
spautin in wild-type cells (Supplementary Fig. 3m, n). Therefore,
a functional CHD6 appears to be required for efficient autophagy
activation in response to DNA damage.
CHD6 chromatin binding and remodeling are not affected by
the HSS mutation in vitro. The HSS-relevant mutation maps to
the CHDCT2 domain of CHD6 (Supplementary Fig. 1a). This
domain was initially identified in CHD4 and then in CHD3 and
CHD546. Low stringency query of the NCBI Conserved Domain
Database (max. E-value= 100) uncovered that the CHD6
CHDCT2 is in fact related to the SLIDE (SANT-Like ISWI)
domain, which has been implicated in DNA binding6,7,47. We,
therefore, tested whether the I1600M mutation affected CHD6
binding to DNA or nucleosomes, in vitro, using purified full-
length wild-type and mutant CHD6, expressed via a baculovirus
system (Supplementary Fig. 5a). mutCHD6 binding was virtually
identical to that of wild-type regardless of the template used, as
judged by electrophoretic mobility shift assays (EMSAs; Supple-
mentary Fig. 5b). This is consistent with our ChIP-seq data (see
Fig. 2a and Supplementary Fig. 2a), and with the fact that the HSS
mutation is not at a lysine or arginine residue, both of which were
shown to be important for DNA binding by SANT-SLIDE
modules7. To exclude that additional DNA binding modules in
CHD6, like its chromodomains48,49, might compensate for the
I1600M mutation, we purified and tested the second putative
CHD6 SANT-SLIDE module alone in EMSAs. Again, wild-type
and mutant CHD6 SANT-SLIDE modules did bind DNA and
nucleosomes with similar efficiencies (Supplementary Fig. 5c, d).
We next tested whether the I1600M mutation impinged on the
remodeling activity of CHD6. Using restriction enzyme accessi-
bility (REA) assays, we observed that the ability of mutCHD6 to
expose RE sites within nucleosomes was indistinguishable from
that of the wild-type protein. This held true regardless of whether
the RE site was near the nucleosome entry/exit site (MfeI site at
+28 bp) or near the pseudo-dyad axis (Hin6I at +71 bp;
Supplementary Fig. 5e). The ability of CHD6 to expose Hin6I
sites should require extensive unwrapping or sliding of the
nucleosome. This contrasts recent work showing that CHD6,
unlike all other subfamily III members, did not slide nucleosomes
in vitro, but only disrupted DNA-histone association in a non-
sliding manner50. Thus, we revisited this aspect using sliding
assays. Addition of full-length wtCHD6 to a nucleosome
positioned at the end of a 227-bp DNA fragment resulted in
the emergence of discrete slower-migrating bands, indicative of
histone octamer repositioning in an ATP-dependent manner
(Supplementary Fig. 5f). Consistent with REA assays, mutCHD6
activity was indistinguishable from that of the wild-type protein.
Finally, we turned to monitoring chromatin remodeling directly
at CHD6 target sites. As CHD6 mostly binds to TSSs between the
−1 and +1 nucleosomes (Supplementary Fig. 5g), we selected a
set of CHD6-bound loci to assess changes in DNA accessibility in
iPSCs. We designed primers overlapping nucleosomes directly
downstream of CHD6 peaks and used them in MNase-qPCR
assays on mononucleosomal templates (Supplementary Fig. 5h, i).
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All sites analyzed showed weak (~20%) to moderate changes
(~40%) in DNA accessibility (Supplementary Fig. 5i), in line with
differences inferred from our ChIP-/RNA-seq data. This was also
validated genome-wide using ATAC-seq; mutCHD6 peaks
exhibited stronger accessibility and their adjacent nucleosome
footprint was slightly repositioned (Supplementary Fig. 5j). In
summary, the HSS mutation does not appear to affect the
enzymatic properties of CHD6 in vitro; however, it does affect
chromatin configuration at CHD6 target loci.
Mutant CHD6 fails to recruit co-factors and activate autop-
hagy genes. Our in vitro data suggest that the I1600M mutation
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does not impede CHD6 association with chromatin or nucleo-
some sliding. However, we saw strong regulatory effects across all
of our HSS-mutant lines. To address this, we first used the I-
TASSER51, HHpred52, and RaptorX53 structure prediction tools,
and uncovered that the CHD6 region between aa 1448 and 1608
likely folds into a structure highly similar to that of the Chd1
SANT-SLIDE domain49 (Fig. 4a, left). Introducing the HSS
mutation in this model returned a distorted interface on top of
the domain (Fig. 4a, right). Consistent with these predictions,
nanoDSF measurements of full-length CHD6 showed that
the mutant unfolds at significantly lower temperatures (Tm:
~41.5 °C) compared to wild-type proteins (~47.7 °C; Fig. 4b), but
without differences in aggregation properties (Fig. 4b, inset).
Taken together, our data suggest that the I1600M mutation may
impact CHD6 folding locally.
Therefore, we asked whether the HSS-mutation interferes with
CHD6 protein–protein interactions. We generated iPSC lines
stably overexpressing full-length wild-type or mutant HA-tagged
CHD6 using a piggybac vector (like in ref. 45; Fig. 4c). Following
24 h of induction with doxycycline, we verified that these lines
expressed similar levels of wt and mutant CHD6 (Fig. 4c,
bottom), prior to co-immunoprecipitating interacting partners. IP
eluates were analyzed via quantitative label-free mass-spectro-
metry. In addition, we also generated CHD6 interactomes upon 2
h of starvation or 1 h of etoposide treatment, and monitored how
mutCHD6 interactions compared to wild-type ones (Supplemen-
tary Data File 2). In steady-state iPSCs, wtCHD6 presented an
interactome consisting of general and specialized transcription
factors, other chromatin remodelers, cell cycle regulators, RNA-
binding proteins related to RNA processing, and factors involved
in rRNA biogenesis (Fig. 4d). When comparing wild-type CHD6
interactors to those of the mutant protein across all three
conditions used, the most consistent finding was the depletion of
chromatin remodeling complex components, especially those
belonging to the BRG-/BRM-associated factor (BAF) and the
Polybromo-associated BAF (PBAF) complexes, like SMARCA4
(BRG1), SMARCC1 (BAF155), or ACTL6A (BAF53; Fig. 4e, f and
Supplementary Fig. 6a, b). Of note, the loss of interaction between
mutCHD6 and SMARCC1 (Fig. 4f) coincided with a loss of
interactions amongst BAF/PBAF components, e.g., between
SMARCC1 and ACTL6A (Supplementary Fig. 6c). Importantly,
this loss was not due to expression changes of the genes involved,
as judged by 3′-end RNA-seq data (Supplementary Data File 3).
Both types of canonical BAF and PBAF SWI/SNF complexes in
humans are crucial for development and differentiation54,55. To
address their connection to CHD6-mediated gene regulation, we
first used SMARCA4, SMARCB1 (INI1), and SMARCC1 ChIP-
seq data from human embryonic stem cells56 and found
remarkable overlap with CHD6-bound positions (Fig. 4g, h).
CHD6 and SMARCB1 ChIP-seq signals were the strongest at
their shared sites, compared to all bound positions (Supplemen-
tary Fig. 6d). All three BAF/PBAF components share 243 genes
with mutCHD6 (and >500 in pairwise combinations; Fig. 4i).
These shared genes were linked to processes such as macro-
autophagy, vacuole organization, apoptosis, cell cycle and DNA
replication, or TORC1 signaling (Fig. 4i). ChIP-qPCR at ten of
these promoters confirmed reduced recruitment of SMARCC1
and ACTL6A to chromatin in both heterozygous and
monoallelic-mutant iPSCs (Fig. 4j), in line with our mass-spec
data (Supplementary Fig. 6a).
To further investigate the connection between CHD6 and BAF/
PBAF, we reanalyzed RNA-seq data from SMARCB1-knockdown
human embryonic stem cells57; 140 SMARCB1-regulated genes
were also bound by CHD6, >40% of which were downregulated,
and associated with lysosomal and vacuole organization, protein
stability, chromatin modifiers, and the p53 pathway (Supple-
mentary Fig. 6e, f). Moreover, the expression of ~40% of all BAF/
PBAF- and CHD6-cobound genes was significantly altered in
mutant compared to wild-type iPSCs in response to autophagy
induction via starvation. This strong deviation from the normal
transcriptional response concerned genes involved in autophagy,
apoptosis, transcription factor activation, the p53 pathway, and
cellular senescence (Fig. 4k). Similarly, ~150 genes co-bound by
the three BAF/PBAF components and CHD6 also showed
misexpression in response to either starvation or etoposide
treatment (Supplementary Fig. 6g, h). As regards the latter, DNA
damage induction caused significant misregulation of 35% of all
BAF/PBAF- and CHD6-bound genes and those genes were linked
to MAPK/p53 signaling, DNA replication, cell cycle, and
inflammation (Supplementary Fig. 6g). In summary, this data
Fig. 3 CHD6 affects the DNA damage response through modulation of autophagy flux. a Western blots (top) showing changes in ATG3 and LC3 levels
in wild-type (wt) and monoallelic mutant iPSCs (mut) that were serum-starved (starv) and/or treated with chloroquine (chlo) or rapamycin (rapa); β-
tubulin levels provide a loading control. Mean normalized band intensities from two experiments (±SD) were quantified and plotted relative to wt levels
(bottom). b FACS profiles (left) of wild-type (wt) or monoallelic mutant iPSCs (mut) transfected with the GFP-LC3-RFP reporter. Plots (right) quantify the
percent of RFP-only iPSCs over all RFP/GFP-double positive plus RFP-only cells in control and 2-h starvation conditions (mean ±SD). *: mean significantly
different from control; P < 0.01, unpaired two-tailed Welsch t-test. c Representative images of wild-type (wt) or monoallelic mutant iPSCs (mut)
immunostained for LC3 (green) and p62 (magenta) in the presence or absence of rapamycin from one experiment are shown. Box plots (mean with
whiskers indicating 95th percentile intervals) quantify the number of puncta, mean signal and extent of LC3/p62 colocalization. *: mean significantly
different from wt; P < 0.01, unpaired two-tailed Welsch t-test. Bar, 5 μM. d As in (c), but for γH2A.X levels (thick black lines indicate IQR, thin lines indicate
95% confidence intervals) after 30-min etoposide (ETO) treatment of wild-type (wt), heterozygous (het), or monoallelic mutant (mut) CMs. *:
significantly different from wt; P < 0.01, Wilcoxon-Mann-Whitney test. Bar, 10 μM. e As in (d), but for γH2A.X (green) and CHD6 (magenta) after
etoposide treatment of iPSCs. The line scan and colocalization index (ci) of the two signal profiles (bottom; γH2A.X foci indicated by arrows) exemplify the
lack of signal overlap. Bar, 5 μM. f Comet assays and quantification of tails in wild-type (wt), heterozygous mutant (het), patient-derived (pat) or
monoallelic mutant (mut) iPSCs treated with etoposide for 30min and allowed 24 h to recover; numbers of cells analyzed (n) are indicated. *: significantly
different from wt; P < 0.05, Wilcoxon-Mann-Whitney test. g As in (f), but for wild-type iPSCs treated with etoposide and allowed to 24 h recover in the
presence or absence of autophagy inhibitors. *: significantly different from wt; P < 0.05, Wilcoxon-Mann-Whitney test. h Bar plots showing percentage
(mean ±SD, n= 3 independent experiments) of wild-type (wt), heterozygous (het) or monoallelic mutant (mut) iPSCs that survived apoptosis, also in the
presence or absence of autophagy inhibitors. *: mean significantly different from wt; P < 0.05, two-tailed unpaired Student’s t-test. i Bar plots showing the
percentage (±SEM, n= 3 independent experiments) of wild-type (wt), heterozygous (het) or monoallelic mutant iPSCs (mut) in the G1, S, or G2 cell cycle
phase upon 0, 10 or 30min of etoposide treatment followed by 24 h recovery. *: significantly different from wt; P < 0.05, two-tailed unpaired Student’s
t-test. j Significantly-enriched GO terms associated with the genes highlighted in (k). k Heatmap showing changes in mRNA levels (log2) of genes
differentially regulated in wild-type iPSCs upon 1 h of etoposide treatment. Those convergently up-/downregulated in monoallelic (mut) and heterozygous
mutant (het) cells are highlighted (magenta/blue rectangles).
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supports the notion that the HSS mutation precludes CHD6 from
recruiting additional chromatin remodeling factors to its target
loci. This may, in turn, affect proper transcriptional control in
response to pro-autophagy or DNA damage cues and lead to
dampened autophagy flux and increased DNA damage burden
(see model in Fig. 5).
Discussion
We exploited a CHD6 de novo mutation linked to the rare
Hallermann-Streiff syndrome to model the disease using isogenic
iPSC lines and investigate the roles of this understudied remo-
deler. Our work uncovers a potentially important role for CHD6
in autophagy regulation, which could explain its ubiquitous
expression across human tissues (The Human Protein Atlas
CHD6 [https://www.proteinatlas.org/ENSG00000124177-CHD6/
tissue]). In line with this, CHD6 displays remarkable overlap of
target loci across very diverse cell types (iPSCs, NCCs, and CMs).
A considerable fraction of these loci is co-bound by TFEB, sug-
gesting that they are primed in resting cells for prompt tran-
scriptional response to pro-autophagy stimuli.
The HSS-relevant I1600M CHD6 mutation does not impact its
ability to bind or remodel chromatin in vitro. Nevertheless,
CHD6-bound genes in mutant cells fail to properly respond to
starvation or DNA damage stimuli, and overexpression of
mutCHD6 results in severe developmental malformations remi-
niscent of the HSS phenotype. We can likely attribute this to the
inability of the mutant CHD6 putative second SANT-SLIDE
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domain to interact with and recruit co-remodelers to its target
promoters. In our proteomics data, the BAF/PBAF complexes
appear as major co-players. The PBAF complex has already been
shown to interact with CHD7 to direct NCC formation via
enhancer regulation54. Interestingly, PBAF was recently also
implicated in stress responses58 and euchromatic DNA lesion
repair59. This aligns well with the fact that CHD6 is exclusively
found in euchromatin (see ref. 18 and own ChIP-seq data), but
not at CHD7 sites, hence representing a separate regulatory cir-
cuit. Moreover, reanalysis of SMARCB1-knockdown deregulated
genes in hESCs (SMARCB1 is a BAF/PBAF subunit operating on
both promoters and enhancers55,60) showed that they overlap
CHD6 at lysosomal, autophagy, and DNA damage response
genes. This further highlights a requirement for multiple, com-
peting or converging, remodeling activities acting at the same loci
to ensure its precise regulation61.
In addition, CHD6 might also function through the regulation
of post-transcriptional steps; it is worth noting that a considerable
subset of CHD6-bound genes is involved in the metabolism and
processing of RNA. CHD6 itself interacts with a number of RNA-
binding and processing factors in our proteomics data. Interac-
tions with many of these factors are specifically hindered fol-
lowing etoposide treatment of CHD6-mutant cells. These
observations possibly further link CHD6 to the control of DNA
damage responses and merit future investigation.
In a recent report implicating it in the oxidative DNA damage
response, CHD6 was shown to be stabilized via reduced degra-
dation and to relocate rapidly to sites of DNA damage21. Like
Moore and co-workers, we saw no change in CHD6 expression
upon etoposide-induced DNA damage (or upon starvation), nor
did CHD6 redistribute to etoposide-induced DNA lesions. Thus,
our data further support that CHD6 is not recruited to DNA
double-strand breaks (but only to sites of oxidative damage).
Given the potential housekeeping role of CHD6 in autophagy in
normal human cells, the accumulation of unrepaired DNA in
CHD6-mutant cells possibly results from impaired autophagy.
With aberrant autophagy also being a cancer hallmark62, the
broad mutational spectrum of CHD6 in cancer specimens might
therefore contribute to the accumulation of tumor-promoting
mutations (COSMIC CHD6 [https://cancer.sanger.ac.uk/cosmic/
search?q=CHD6]).
Increased burden of poorly resolved DNA damages is also a
hallmark of ageing, and mutations in the DNA damage response
machinery give rise to premature ageing-like phenotypes, as seen
in ERCC1-63 or XPA-deficient cells64. We observed acquisition of
senescence-like features in CHD6-mutant cells. Interestingly,
mutations in some SWI/SNF subunits also accelerate cellular
ageing65. Our data suggest that CHD6 operates upstream of these
changes by coordinating autophagy and DNA damage responses
across cell types. In line with this, the key regulator p62 normally
mediates the effects of autophagy onto DNA repair mechanisms,
likely in conjunction with p5366; this is gradually impaired with
age, but restored via lifespan-extending interventions26. In
CHD6-mutant cells, p62 levels are lower and the autophagy-to-
DNA damage repair axis disturbed. Thus, we propose that defi-
cient autophagy-driven DNA damage burden and the induction
of cellular ageing processes contribute to the onset and progres-
sion of HSS.
Methods
Whole-exome sequencing (WES) and reprogramming of HSS fibroblasts.
Exonic and adjacent intronic sequences were enriched from genomic DNA isolated
from blood and saliva of the index patient and the parents using the NimbleGen
SeqCap EZ Human Exome Library v2.0 enrichment kit, and sequenced on a
HiSeq2000 platform (Illumina). WES data analysis and filtering of mapped targeted
sequences was carried out using the “Varbank” exome and genome analysis
pipeline v2.6 of the Cologne Center for Genomics (CCG, University of Cologne,
Fig. 4 The I1600M CHD6 mutation hinders co-factor recruitment at autophagy gene promoters. a In silico rendering of the second putative SANT-SLIDE
domain structure for wild-type and mutant CHD6 (based on the published Chd1 SANT-SLIDE structure7) and zoomed views around the I1600M mutation
(bottom). b NanoDSF melting profiles (first derivative of the 350/330 nm ratio; n= 3 independent runs) of FLAG-tag purified wild-type (dark blue) or
I1600M (light blue) full-length CHD6 along a temperature gradient. *: significantly different mean; P < 0.01, two-tailed unpaired Student’s t-test. Scattering
profiles along the gradient reveal no difference in aggregation (inset). c Overexpression of wild-type or mutant CHD6 cloned into a piggybac vector (left) in
iPSCs exemplified by Venus-GFP levels or anti-HA western blotting of CHD6 (right); β-tubulin provides a control. Bar, 25 μM. d Network representation of
GO terms associated with proteins co-purifying with wild-type CHD6 in steady-state iPSCs. e Heatmaps showing enrichment or depletion of GO terms/
pathways linked to CHD6-interacting proteins upon starvation, etoposide treatment or in steady-state wild-type and mutant iPSCs. f Western blot of
SMARCC1 co-immunoprecipitating with overexpressed wild-type (wt) or mutant CHD6 (mut) in iPSCs; anti-HA and anti-β-tubulin blots provide a control.
g Representative genome browser views for SMARCA4/-B1/-C1 ChIP-seq aligned to CHD6 ChIP-seq from wild-type (wt) and monoallelic mutant iPSCs
(mut) around the DNAAF1 and LAMP1 promoters. h Line plots showing average SMARCA4/-B1/-C1 ChIP-seq signal profiles in the 4 kbp around CHD6
peaks; signal from mutCHD6 ChIP-seq provides a reference. i Venn diagram (left) showing overlap of genes bound by mutCHD6 and SMARCA4/-B1/-C1.
Bar plots (right) showing significantly-enriched GO terms associated with the 243 shared genes. *: significantly more than expected by chance; P < 10−3,
hypergeometric test. j Bar plots showing changes in SMARCC1 or ACTL6A ChIP-qPCR signal (fold enrichment over wt ±SD; n= 2 independent
experiments) from heterozygous (white) or monoallelic mutant iPSCs (blue). k Heatmaps (left) showing changes in mRNA levels (log2) in response to
iPSC starvation at genes co-bound by CHD6 and SMARCA4/-B1/-C1. Pearson’s correlation coefficients for each pair are shown. Bar plots (right) showing
significantly-enriched GO terms associated with these genes.
Fig. 5 A model for HSS-relevant effects of the CHD6 mutation. In
individuals with wild-type CHD6 (top), co-recruitment of CHD6 and BAF/
PBAF complexes to the promoters of autophagy genes ensure proper gene
regulation in response to pro-autophagy and stress cues. In those carrying
the I1600M mutation, the recruitment of BAF/PBAF co-factors is hindered
and autophagy control is deregulated; as a result, the DNA damage
response is compromised, senescent cell features emerge, and cell
differentiation and specification processes can be impacted.
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Germany); we obtained a mean coverage of 75–95 reads, with 95.9–96.7% of target
sequences covered more than 10×. Trio-WES data were filtered for high quality
(coverage of >6 reads, minimum quality score of 10), rare autosomal recessive and
de novo variants (i.e., with minor allele frequency of <0.5% in the 1000 Genomes
database, the Exome Aggregation Consortium browser, and not annotated in all in-
house WES datasets of the CCG). Primary fibroblasts from the index patient were
isolated via standard skin biopsy, and all downstream work was performed in
accordance to the Helsinki Declaration protocols and reviewed and approved by
the local institutional Ethics boards (University Hospital Cologne, Germany;
University Medical Center Göttingen, Germany).
iPSC culture and differentiation into cardiomyocytes or neural crest cells.
iPSCs were grown in FTDA media67. Once confluent, cells were dissociated using
accutase at 37 °C for 10 min (Sigma-Aldrich) and 450–600,000 cells were seeded
per well of a 6-well plate. Differentiation into cardiomyocytes68 used confluent
iPSCs that were dissociated into single cells using accutase. Cells were then counted
and 600,000 cells for each well of a 24-well plate were aliquoted and spun for 2 min
at 300 × g at room temperature. The cell pellet was resuspended in ITS medium
(knockout DMEM, 1 × x penicillin/streptomycin/glutamine, 1× ITS supplement,
10 μM Y-27632, 25 ng/ml FGF2, 1–2 ng/ml BMP4 and 1–2 μM CHIR99021) and
seeded in matrigel-coated 24-well plates. Note that wt-iPSCs required 1.75 μM and
1.25 ng/ml, mut-iPSCs required 1.75 μM and 2 ng/ml, and patient-derived iPSCs
required 1.75 μM and 1.75 ng/ml of CHIR and BMP4, respectively, for differ-
entiation. To ensure the equal distribution and attachment of cells, plates were
moved crosswise, tapped several times and left for 20 min at room temperature
before being transferred into the incubator. After 24 h, ITS growth medium was
replaced by TS medium [knockout DMEM, 1x penicillin/streptomycin/glutamine,
1× TS supplement (100× stock: 5.5 μg/ml Transferrin and 6.7 ng/ml Sodium
Selenite in 100 ml sterile PBS), and 250 μM 2-phospho-L-ascorbic acid]. After 48 h,
TS medium was replenished and supplemented with 10 μM of the Wnt-inhibitor
IWP-2 for 48 h. After 48 h, media were changed to fresh TS until beating cells were
observed on day 8. At this point, the medium was changed back to knockout
DMEM supplemented with 2% FCS, L-glutamine and 1× penicillin/streptomycin
for maintenance until cells were used for downstream analysis. Differentiation into
neural crest cells36 used iPSCs clusters transferred into neural induction media
[NIM; 1:1 ratio of DMEM-F12 (Invitrogen #10565-018) and Neurobasal media
(Invitrogen #21103-049) complemented with 0.5× N2, 0.5× B27, 5 µg/ml insulin,
20 ng/ml βFGF, 20 ng/ml EGF, 1× pen/strep] in uncoated polypropylene dishes.
Cell-spheres/-rosettes were then allowed to spontaneously attach and after
6–9 days hNCLCs (human neural crest-like cells) migrated out of these. Subse-
quently, rosettes were dissected away and P0-isolated NCLCs were dissociated
using accutase and replated for 10–15 days of maintenance in NIM in dishes coated
with 1 µg/ml fibronectin.
Generation of isogenic iPSC lines via CRISPR-Cas9 genome editing. gRNAs
were designed against DNA stretches within exon 31 of CHD6 or its preceding
intron using an online tool [http://crispr.mit.edu]. Each gRNA was assembled from
two complementary oligonucleotides containing the “NGG” PAM sequence and
distinct 4 bp-overhangs (“CACC” and “AAAC”) allowing for cloning into the BbsI
restriction site of the pX330A vector69. Then, a single-stranded oligonucleotide
donor (ssODN)70 or a plasmid carrying homology arms71 were provided as tem-
plates for homologous recombination. iPSCs were seeded at low density in a 6-well
plate (175,000 cells/well) and transfected 12 h later by the dropwise addition of a
mixture of 200 µl OptiMEM (Invitrogen), 12 µl FuGene HD (Promega) and a total
of 3 µg from all plasmids. After 24 h, GFP expression was detectable micro-
scopically; transfection efficiency was estimated to be ≥60%. Cells were then
selected in 0.5 µg/ml puromycin for 24 h and reseeded in clonal dilution
(5000–8000 cells/well of a 6-well plate). Individual clones were screened using PCR
and, ultimately, insertion of the desired mutation was verified by Sanger sequen-
cing. As control lines, two “no gRNA” iPSC clones and two transfected with a
gRNA targeting the “safe harbour” AAV locus on chr19 were used interchangeably.
All gRNAs/ssODNs used are listed in Supplementary Data File 4.
CytoScan genome analysis of iPSC lines. Genome integrity of all CRISPR-edited
and reprogrammed iPSC lines was assessed using CytoScan HD microarray
technology (ThermoFisher Scientific), which allows reliable detection of 25–50
kbp-long copy number changes genome-wide. For this analysis, intact genomic
DNA was isolated using the Quick DNA Miniprep kit (Zymo Research) as per the
manufacturer’s instructions, and data analyzed via the ChAS suite v4.0 against the
reference genome assembly (hg19). A summary is provided in Supplementary Data
File 1.
Generation and analyses of total RNA-seq. Cells from different genotypes/dif-
ferentiations were harvested in Trizol (Life Technologies) and total RNA was
isolated and DNase-treated using the Direct-zol RNA miniprep kit (Zymo
Research) as per the manufacturer’s instructions. In the case of cardiomyocytes,
cells at day 10–11 of differentiation were used, while in the case of NCCs, cells were
obtained by collecting migratory cells from dissected and re-plated rosettes. Bar-
coded cDNA libraries were generated using the TruSeq RNA library kit (Illumina)
via selection on poly(dT) beads. The resulting libraries were paired-end sequenced
to >50 million read pairs on a HiSeq4000 platform (Illumina). Transcript quan-
tification was performed using Kallisto v0.44.072, which pseudoaligns RNA-seq
reads to transcripts (Ensembl annotation used: GRCh37, comprising all known
protein-coding sequences from hg19). After transcript quantification, pseudo-
counts were further processed via Sleuth73, which bootstraps Kallisto output to
ascertain and correct for technical variation. To test for association between gene
expression and genotype, we created a linear model and tested the effect of the
CHD6 mutation in each cell type via gene-level analysis. P-values were corrected
for multiple hypothesis testing using the Benjamini-Hochberg algorithm and an
FDR < 0.05 as a significance threshold for all figures and tables. Data preprocessing
and visualization were performed using R v3.3.3 and Bioconductor v3.4, and GO
term enrichment using Metascape74. Differentially-regulated genes per each line
are listed in Supplementary Data File 5. For qPCR, the SYBR Green JumpStart Taq
ReadyMix (Sigma-Aldrich) was used as per the manufacturer’s instructions.
3′-end RNA sequencing and analysis. 3′-end RNA-seq was used as a lower-cost
alternative to mRNA-seq to interrogate multiple conditions and genotypes.
Libraries were prepared from total RNA using the QuantSeq 3′ mRNA-Seq Library
Prep Kit (Lexogen), and single-end sequenced on a HiSeq4000 platform (Illumina)
generating ~15 × 106 100 nt-long reads per sample. Reads were quality assessed and
mapped to hg19 using STAR75. Reads uniquely mapping to exons were quantified
using HTSeq-count and differential gene expression was assessed using DESeq276.
Differentially-regulated genes per each cell line and treatment are listed in Sup-
plementary Data File 3.
ChIP-seq and data analysis. For each batch of ChIP experiments, ~12 million
cells were crosslinked in 2% PFA for 45 min at 4 °C. From this point onward, cells
were processed via the ChIP-IT High Sensitivity kit (Active motif) as per the
manufacturer’s instructions, but using the NEXSON protocol for nuclei isolation77.
Chromatin was sheared to 200–500-bp fragments on a Bioruptor Plus (Diagenode;
2× 20–26 cycles of 30 s “on” and 30 s “off” at the highest power setting), and
immunoprecipitations were carried out by adding 4 μg of the appropriate anti-
bodies (CHD6, Bethyl A301-221A; TFEB, Bethyl A303-673A) to ~30 μg of chro-
matin and incubating on a rotator overnight at 4 °C in the presence of protease
inhibitors. Following addition of protein-A/G agarose beads and washing, DNA
was purified using the ChIP DNA Clean & Concentrator kit (Zymo Research) and
used in qPCR or sequencing on a HiSeq4000 platform (Illumina). qPCRs were
performed with the primers listed in Supplementary Data File 4. Where ChIP-seq
was performed, at least 20 million reads were obtained, also for the relevant “input”
samples. Raw sequencing reads (typically 50 nt-long) were analyzed using the
HiChIP pipeline78, and peaks were called using MACS279. Thresholded CHD6
ChIP-seq peaks (q-value <0.05) per each cell type and genotype are listed in
Supplementary Data File 6. For plotting ChIP-seq signal coverage over select
regions, ngs.plot was used80.
Immunostaining and imaging. Cells were grown on coverslips, fixed in 4% PFA/
PBS for 10 min at room temperature, washed in 1× PBS, permeabilized in 0.5%
Triton-X/PBS for 5 min at room temperature, blocked in 1% BSA/PBS for 1 h
before incubating with the primary antibody of choice for 2 h to overnight. Cells
were next washed twice in 1x PBS for 5 min, before incubating with the appropriate
secondary antisera for 1 h at room temperature. Nuclei were counterstained with
DAPI (Sigma-Aldrich) for 5 min, washed, and coverslips mounted onto slides in
Prolong Gold Antifade (Invitrogen). For image acquisition, a widefield Leica DMI
6000B with a HCX PL APO 63×/1.40 (Oil) objective was used, making sure
exposure times were maintained constant across samples in each imaging session
for the same immunostaining. Finally, images were analyzed using the Fiji suite81
as follows. First, background signal levels were subtracted using the embedded
function (rolling ball function of 50-px radius with a sliding paraboloid and dis-
abled smoothing), and the DAPI channel was used to determine the area of interest
where signal would be quantified from. Measured mean signal intensities were used
to generate plots in R or via InstantClue82. For bean plots, dots represent the mean
of the dataset; for box plots, whiskers ends represent the top and bottom quantiles,
respectively.
Analysis of autophagy flux. To measure autophagy flux, iPSCs were transiently
transfected with a plasmid coding for a tandemly-tagged GFP-LC3-mRFP41. 48 h
after transfection, cells were incubated in starvation medium or complete FTDA
medium for 2 h before being lifted using accutase diluted by F12 media and sup-
plemented with 10 μM of the Y27632 inhibitor to prevent apoptosis. Next, iPSCs
were pelleted and resuspended in 150 μl of complete FTDA or starvation medium
again supplemented with Y27632 inhibitor to undergo FACS analysis. Cell were
counted in a TC20 Automated cell counter (BioRad) and 100,000 cells of each
genotype and treatment were stained with Zombie-NIR viability solution (1:1000;
BioLegend) as per the manufacturer’s instructions to exclude dead cells from the
analysis. iPSCs overexpressing GFP or RFP only were used in parallel as baseline
controls, and non-transfected cells served as a negative control. Measurements
were performed on a Cytek Aurora flow cytometer and data analysis was per-
formed via the SpecroFlo software. The percentage of cells carrying fused
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autolysosomes was estimated as a proportion of mRFP-positive cells out of total
number of mRFP/GFP-double positive cells from two experiments.
Comet assays. Comet assays were performed according to a standard protocol83.
Briefly, cells were treated with 30 µg/ml etoposide for 30 min, harvested with
accutase to prepare a single-cell suspension, counted, and diluted to a cell density
of ~2 × 104 cells/ml in PBS without bivalent cations, on ice. Electrophoresis slides
were covered with low-melting agarose, alkaline lysis was allowed to run overnight,
before slides were submerged in rinse solution for 20 min, the solution exchanged
another 2 times to ensure removal of salts and detergents, and finally submerged in
an electrophoresis chamber filled with fresh wash buffer. Electrophoresis proceeded
for 25 min at a constant current of 40 mA, before slides were neutralized in distilled
water, placed in staining solution containing 2.5 µg/ml of propidium iodide for 20
min, and rinsed again in water. For analysis, CometScore [http://rexhoover.com/
index.php?id=cometscore] was used with doublets or comets at slide edges dis-
carded from analysis. The length and intensity of DNA “tails” relative to “heads”
were used as proxies for the amount of DNA damage in individual nuclei.
Generation of stable CHD6 overexpression lines, immunoprecipitation, and
proteomics. Full-length CHD6 cDNA lacking the stop codon was PCR-amplified
from wild-type NCC cDNA and cloned into a piggyback backbone (Ka0717_pPb-
hCMV-cHA-IRES Venus)68 between the MluI and SpeI restriction sites, thus
positioning the CHD6 cDNA in frame with a C-terminal HA-tag. The HSS-
relevant mutation (C4800G) was introduced to the wtCHD6 piggybac vector using
site-directed mutagenesis. Wild-type iPSCs were transfected as described above,
using the wt- or mutCHD6-containing piggybac together with a transposase-
expressing vector enabling few random integrations of the construct into the
genome. Individual clones were selected after clonal dilution and selection on the
basis of high Venus signal. CHD6 overexpression was confirmed by immuno-
fluorescence and western blots using anti-HA antisera. Following overexpression,
wt/mutCHD6 immunoprecipitation was performed on freshly-harvested doxycy-
cline-induced iPSCs. First, cell nuclei were isolated by incubating cells for 15 min
on ice in NIB buffer (15 mM Tris-HCL pH 7.5, 60 mM KCl, 15 mM NaCl, 5 mM
MgCl2, 1 mM CaCl2, 250 mM sucrose) containing 0.3% NP-40. Nuclei were pel-
leted for 5 min 800 × g at 4 °C, washed twice in the same buffer, lysed for 10 min on
ice in IP buffer (150 mM LiCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5%
Empigen) freshly supplemented with 2 mM sodium vanadate, 1× protease inhibitor
cocktail (Roche), PMSF (10 µl), 0,5 mM DTT, 5 µl Caspase inhibitor III (Calbio-
chem), and 50 units Benzonase per ml of IP buffer, before preclearing cell debris by
centrifugation at >15,000 × g at 4 °C. Finally, 1 mg of the lysate was incubated with
anti-HA antisera overnight at 4 °C. Magnetic beads (Active Motif) were then
washed once with 1× PBS-Tween and combined with the antibody-lysate mixture.
Following a 2-h incubation at 4 °C, beads were separated on a magnetic rack and
washed 5×, 5 min each in wash buffer (150 mM KCl, 5 mM MgCl2, 50 mM Tris-
HCl pH 7.5, 0.5% NP-40) and another two times in wash buffer without NP-40.
Captured proteins were predigested and eluted from the beads using digestion
buffer (2M Urea, 50 mM Tris-HCl pH 7.5, 1 mM DTT) supplemented with trypsin
and eluted from the beads with elution buffer (2 M Urea, 50 mM Tris-HCl pH 7.5,
5 mM chloroacetamide) supplemented with trypsin and LysC, before subjected to
mass-spectrometry on a Q-Exactive Plus Orbitrap platform coupled to an EASY
nLC (Thermo Scientific). Peptides were loaded in solvent A (0.1% formic acid in
water) onto an in-house packed analytical column (50 cm length, 75 µm I.D., filled
with 2.7 µm Poroshell EC120 C1; Agilent); were chromatographically separated at a
constant flow rate of 250 nL/min using the following gradient: 3–8% solvent B
(0.1% formic acid in 80% acetonitrile) for 1 min, 8–30% solvent B for 39 min,
30–50% solvent B for 8 min, 50–95% solvent B for 0.3 min, followed by washing
and column equilibration. The mass spectrometer was operated in data-dependent
acquisition mode. An MS1 survey scan was acquired from 300–1750m/z at a
resolution of 70,000. The top 10 most abundant peptides were isolated within a 1.8
Th window and subjected to HCD fragmentation at a normalized collision energy
of 27%. The AGC target was set to 5e5 charges, allowing a maximum injection time
of 110 ms. Product ions were detected at a resolution of 35,000; Precursors were
dynamically excluded for 10 s. All raw data were processed with Maxquant
(v1.5.3.8) using default parameters. Briefly, MS2 spectra were searched against the
Uniprot HUMAN.fasta (16.06.2017) database, including a list of common con-
taminants. False discovery rates on were estimated by a target-decoy approach to
1% (Protein FDR) and 1% (PSM FDR), respectively. The minimal peptide length
was set to 7 amino acids and carbamidomethylation at cysteine residues was
considered as a fixed modification. Oxidation (M) and Acetyl (Protein N-term)
were included as variable modifications. The match-between runs option was
enabled and LFQ quantification was enabled under default settings. The full list of
peptide hits and their analysis is provided in Supplementary Data File 2.
Western blotting. Western blotting was performed as previously described45. In
brief, ~2 × 106 cells were enzymatically detached or gently scraped off cell culture
dishes, and pelleted for 5 min at 600 × g. The supernatant was discarded, and the
pellet resuspended in 100 µl of ice-cold RIPA lysis buffer containing 1× protease
inhibitor cocktail (Roche), incubated for 30 min on ice, and centrifuged for 15 min
at >15,000 × g to pellet cell debris and collect supernatant. Total protein
concentrations were determined using the Pierce BCA Protein Assay Kit (Ther-
moFisher Scientific), before extracts were stored at −80 °C. Proteins were resolved
by SDS-PAGE, transferred onto membranes using the TransBlot Turbo setup (Bio-
Rad), and detected using the antibodies and dilutions listed in Supplementary
Table 1. Raw scans of the membranes from all western blots presented in this study
can be found in the Source data file online.
MNase nucleosome isolation and qPCR. iPSCs were grown in 6-well plates to
~80% confluency and rinsed with PBS prior to addition of 1 ml of freshly prepared
permeabilization buffer (15 mM Tris/HCl pH 7.6; 60 mM KCl; 15 mM NaCl; 4 mM
CaCl2; 0.5 mM EGTA; 300 mM sucrose; 0.2% NP-40; 0.5 mM β-mercaptoethanol
supplemented with MNase (Sigma) at 1 μ/ml final concentration. MNase was
added for 3 min at 37 °C, and stopped by addition of an equal volume of stop buffer
(50 mM Tri/HCl pH 8.0; 20 mM EDTA; 1% SDS). Finally, 250 µg RNase A
were added for 2 h at 37 °C, followed by addition of 250 µg proteinase K and
incubation at 37 °C overnight. Next day, DNA was isolated via standard phenol-
chloroform extraction, digestion efficiency was determined after electrophoresis in
1% agarose gels, and mononucleosomal DNA was isolated from the gel. Nucleo-
some occupancy was assessed by qPCR using the primers listed in Supplementary
Data File 4.
SA-ß-gal staining, organelle detection, and cell cycle analyses. Senescence-
associated β-galactosidase assays (Cell Signaling) were performed as per the
manufacturer’s instructions before manually counting positive cells. Acidic orga-
nelles were visualized using Lysotracker Deep Red (ThermoFisher) as per the
manufacturer’s instructions. Cell cycle analysis was performed using live cell
nuclear staining with RedDot1 (Biotum) as per the manufacturer’s recommenda-
tions, and flow cytometry data were analyzed using FlowJo [https://www.flowjo.
com/]. For autophagy inhibition prior to etoposide treatment, 10 μM chloroquine
or 2 μM spautin were used. In all cases, cells were pretreated with the inhibitor of
choice for 2 h prior to etoposide treatment (30 μg/ml) for 30 min (10 μm chlor-
oquine, 500 μM rapamycin or 250 nM bafilomycin A1). Cells were next rinsed with
sterile PBS, and fresh medium with or without replenished inhibitors was added for
overnight incubation. Finally, cells were collected using accutase and counted
before performing comet assays.
In vitro and in vivo migration assays. For in vitro migration (scratch) assays,
wild-type and patient-derived NCCs were grown in 6-well plates and one scratch
per well was manually inflicted using a sterile cell scraper. Cell migration into the
scratch was monitored for up to 8 h in 2-h increments by brightfield microscopy.
For in vivo migration assays, GFP-labeled wild-type and mutant iPSCs were dif-
ferentiated into NCCs as described above. Using a blunt glass capillary, NCCs were
lifted with the help of accutase and inserted into the developing anterior neural
region (i.e., midbrain) of chicken embryos at stage HH9. Operated eggs were
resealed with medical tape and incubated until stages HH20, when embryos were
isolated and fixed in 4% PFA for immunofluorescence; GFP was detected using
anti-GFP antisera (TP401, OriGene).
In vivo CHD6 overexpression in chicken embryos. For in vivo CHD6 over-
expression, electroporation of chicken embryos37 was performed on eggs from
stage HH9-10 that were windowed and had the extraembryonic membrane par-
tially removed. A vector containing mutant or wild type CHD6 ORFs
(Ka0717_pPb-hCMV-cHA-IRES Venus-CHD6m and Ka0717_pPb-hCMV-cHA-
IRES Venus-CHD6m; this paper) were first mixed 9:1 with the plasmid encoding
the transposition transactivator, and this mixture then mixed 2:1 with Fast Green
solution (Sigma) and microinjected into the neural tubes of the embryos. The
neural tube was then electroporated with 5x square pulses of 20 V/20 msec using
the Intracel TSS20 Ovodyne electroporator, eggs were resealed with tape and re-
incubated for 24 h, before tape was removed and 10 µl of 2 µg/ml doxycycline were
added at the site of electroporation and eggs were sealed again and re-incubated
until stage HH20, where heart dissections also took place. CHD6 overexpression
was confirmed in transgenic embryos on the basis of GFP signal under an Olympus
SZX16 stereomicroscope with an EXFO X-cite series 120PC Q apparatus. Under
German law, experiments on fertilized eggs performed up until stage HH20 do not
require animal ethics approval.
CHD6 protein expression and purification and in vitro assays. Steps from
cloning to protein expression and purification were carried out as described
previously48. In brief, WT and mutant I1600M CHD6-HA cDNAs were cloned
into pFastBac1 and the HA tag was replaced by a FLAG tag using PCR and Gibson
assembly. SANT-SLIDE 2 domain constructs were generated by PCR with a primer
introducing a FLAG tag at the 3′ end. Baculoviruses were all produced via the Bac-
to-Bac Baculovirus Expression Systems manual (ThermoFisher). CHD6-FLAG
protein constructs were purified from 4 liters of Sf9 cell cultures. Cells were
resuspended in BC buffer (10% Glycerol, 20 mM HEPES, pH 7.9, 0.4 mM EDTA,
freshly supplemented with β-mercaptoethanol and protease inhibitors) containing
250 mM NaCl (BC 250). Cells were lysed by 2 freeze–thaw cycles, and cell extracts
were cleared by centrifugation prior to adding M2-affinity (anti-FLAG) gel (Sigma)
for 4 h, at 4 °C. The extracts were then poured into Econo columns (Bio-Rad), and
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the flow-through was reapplied once. The retained M2-beads were washed twice
with at least 10 resin volumes of: BC 250, BC 500, BC 1000 and once with about 10
resin volumes of BC 500, BC 250. The last wash was performed with 10 resin
volumes of BC 100 prior to elution with BC 100 containing 0.25 mg/ml of FLAG-
peptide (Sigma). Purified proteins were used in electrophoretic mobility shift assays
(EMSA), in nucleosome mobilization/sliding, and in restriction enzyme accessi-
bility (REA) assays using DNA and nucleosome substrates as described
previously48, but using non-radioactive substrates. Detection and quantification of
the substrates was achieved via staining with SYBR Gold Nucleic Acid Gel Stain
(ThermoFisher).
NanoDSF CHD6 thermal stability determination. For thermal unfolding
experiments, full-length wildtype and I1600M CHD6 protein preparations were
diluted to a final concentration of 150 nM in EX80 buffer, and 10 μL of each sample
per capillary was prepared. The samples were loaded into high sensitivity UV
capillaries, and measurements were carried out on a Prometheus NT.48 instrument
with a temperature gradient set to increase 1 °C/min in the range of 20 °C to 90 °C
and independently replicated twice.
Assay for transposase-accessible chromatin using sequencing (ATAC-seq)
and data analysis. Tn5 transposase-accessible chromatin was isolated from iPSCs
according to the standard ATAC-seq protocol84 with one modification aiming at
quantitative scaling of the resulting data. In brief, 105 iPSCs per replicate we
“spiked” with 200 D. melanogaster S2 cells, washed in 1× PBS and added to lysis
buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% NP-40, 0.1%
Tween-20, and 0.01% digitonin) for 3 min85 to isolate nuclei. Nuclei were next
washed in washing buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2,
0.1% Tween-20) and pelleted by centrifugation. Isolated nuclei were resuspended in
transposase reaction mix (25 μl 2× TD buffer, 16.5 μl 1× PBS, 0.5 μl 10% Tween-20,
0.5 μl 1% digitonin, 2.5 μl Tn5, and 5 μl nuclease-free H2O) and incubated at 37 °C
for 30 min on Thermomixer under constant shaking at 1000 rpm. The transposi-
tion reaction was terminated by the addition of stop buffer (50 mM Tris-HCl pH 8,
10 mM EDTA, 1% SDS), and DNA purified using the DNA Clean & Concentrator
kit (Zymo Research). Following standard library generation, samples were
sequenced to >50 million read pairs on a NovaSeq6000 platform (Illumina). Read
pairs were mapped to the hg38 and dm6 reference genome builds for human and
Drosophila, respectively, using Bowtie286. Non-primary, unmapped, duplicate, and
mitochondrial reads were removed. Data mapping to the Drosophila genome were
used in ChIPSeqSpike [https://bioconductor.org/packages/release/bioc/html/
ChIPSeqSpike.html] for calculating scaling factors in order to produce RPKM-
normalized scaled coverage.
Statistics and reproducibility. P-values associated with Student’s/Welsch t-tests
were calculated using GraphPad [http://graphpad.com/], and those associated with
the Wilcoxon-Mann-Whitney test using the EDISON-WMW [https://ccb-
compute2.cs.uni-saarland.de/wtest/] online tool. Unless otherwise stated, only P-
values <0.01 were deemed as significant. Also note that for immunofluorescence
analyses, representative images from one of at least two independent and con-
verging experiments are displayed and quantified.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All NGS data generated in this study are available at the NCBI Gene Expression
Omnibus (GEO) via GSE135832 and GSE136057 accession numbers. Publicly available
SMARCB1-knockdown RNA-seq from hESCs can also be found at GEO under accession
number GSE128351, SMARCA4/B1/C1 iPSC ChIP-seq data under accession number
GSE124903, CHD1/2 and CHD7 hESCs ChIP-seq were generated by the ENCODE
Consortium and can be found under accession numbers GSE31477 and GSE29611,
respectively, H3K4me3 ChIP-seq under accession number GSE29611, and DNase I
hypersensitivity and FAIRE-seq data from hESCs under accession numbers GSE32970
and GSE35239, respectively. All proteomics data are available via the PRIDE
ProteomeXchange Consortium repository87 under the dataset identifier PXD024803. All
other data are available from the corresponding authors upon reasonable request. Source
data are provided with this paper.
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